BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16581570)

  • 1. Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity.
    van de Kerkhof PC; Kragballe K; Austad J; Berth-Jones J; Cambazard F; de la Brassinne M; Ljungberg A; Murphy G; Papp K; Wozel G
    Eur J Dermatol; 2006; 16(2):167-71. PubMed ID: 16581570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.
    Bruins FM; Bronckers IMGJ; Groenewoud HMM; van de Kerkhof PCM; de Jong EMGJ; Seyger MMB
    JAMA Dermatol; 2020 Jan; 156(1):72-78. PubMed ID: 31774449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
    Bożek A; Reich A
    Adv Clin Exp Med; 2017 Aug; 26(5):851-856. PubMed ID: 29068583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature.
    Puzenat E; Bronsard V; Prey S; Gourraud PA; Aractingi S; Bagot M; Cribier B; Joly P; Jullien D; Le Maitre M; Paul C; Richard-Lallemand MA; Ortonne JP; Aubin F
    J Eur Acad Dermatol Venereol; 2010 Apr; 24 Suppl 2():10-6. PubMed ID: 20443995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
    Jacobson CC; Kimball AB
    Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.
    Yao DN; Lu CJ; Wen ZH; Yan YH; Xuan ML; Li XY; Li G; He ZH; Xie XL; Deng JW; Guo XF; Ou AH
    Trials; 2016 Mar; 17(1):140. PubMed ID: 26983642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin for the treatment of plaque-type psoriasis.
    Faghihi T; Radfar M; Mehrabian Z; Ehsani AH; Rezaei Hemami M
    Pharmacotherapy; 2011 Nov; 31(11):1045-50. PubMed ID: 22026392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters.
    Armstrong AW; Parsi K; Schupp CW; Mease PJ; Duffin KC
    JAMA Dermatol; 2013 May; 149(5):577-82. PubMed ID: 23426158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial Intelligence-Based Psoriasis Severity Assessment: Real-world Study and Application.
    Huang K; Wu X; Li Y; Lv C; Yan Y; Wu Z; Zhang M; Huang W; Jiang Z; Hu K; Li M; Su J; Zhu W; Li F; Chen M; Chen J; Li Y; Zeng M; Zhu J; Cao D; Huang X; Huang L; Hu X; Chen Z; Kang J; Yuan L; Huang C; Guo R; Navarini A; Kuang Y; Chen X; Zhao S
    J Med Internet Res; 2023 Mar; 25():e44932. PubMed ID: 36927843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between quality of life and the severity of psoriasis in Turkey.
    Çakmur H; Derviş E
    Eur J Dermatol; 2015 Apr; 25(2):169-76. PubMed ID: 25655046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining and treating moderate plaque psoriasis: a dermatologist survey.
    Knuckles MLF; Levi E; Soung J
    J Dermatolog Treat; 2018 Nov; 29(7):658-663. PubMed ID: 29502473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis.
    Bergstrom KG; Arambula K; Kimball AB
    Cutis; 2003 Nov; 72(5):407-11. PubMed ID: 14655784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    Am J Clin Dermatol; 2017 Aug; 18(4):583-590. PubMed ID: 28342016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.
    Robinson A; Kardos M; Kimball AB
    J Am Acad Dermatol; 2012 Mar; 66(3):369-75. PubMed ID: 22041254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI).
    Matza LS; Brazier JE; Stewart KD; Pinto L; Bender RH; Kircik L; Jordan J; Kim KJ; Mutebi A; Viswanathan HN; Menter A
    J Med Econ; 2019 Sep; 22(9):936-944. PubMed ID: 31161828
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort.
    Walsh JA; McFadden M; Woodcock J; Clegg DO; Helliwell P; Dommasch E; Gelfand JM; Krueger GG; Duffin KC
    J Am Acad Dermatol; 2013 Dec; 69(6):931-7. PubMed ID: 24054760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.